Sanofi to sell 97% of its stake in Regeneron; shares fall 3%
French drug maker Sanofi’s share price fell 3.3% after plans to exit US biotech firm Regeneron were made public.
French pharmaceutical group Sanofi announced on Tuesday 26 May 2020 that it has agreed to sell 11.8 million shares of US biotech firm Regeneron Pharmaceuticals' (NASDAQ: REGN) common stock through a registered offering at a price of US$515.00 per share.
Sanofi shares fell 3.3% following the announcement, while Regeneron saw its share price decline as much as 5.5% on an intra-day basis, based on IG trading data.
As at 10:00 CET on Wednesday 27 May 2020, Sanofi stocks are trading at 86.67 euros apiece.
IG is a world-leading online trading and investments provider for thousands of financial markets. With CFDs (read about CFDs here), you can buy long or sell short on Sanofi, Regeneron Pharmaceuticals and other healthcare stocks depending on whether you think prices will rise or fall. Start today by opening a live or demo IG account.
Share sale will result in US$12 billion pay-out for Sanofi
As part of the sale agreement, Regeneron will repurchase 9.8 million shares or US$5 billion in common stock from Sanofi at the offering price less the underwriting discount, as previously announced.
In connection with the offering, the underwriters have been granted an option to purchase up to 1.2 million additional Regeneron shares at the price payable by the underwriters in the offering, exercisable within the next 30 days.
If the option is fully exercised, the offering and repurchase will together result in gross proceeds to Sanofi of US$11.7 billion and the sale of Sanofi’s entire holding in Regeneron, excluding 400,000 Regeneron shares that Sanofi will continue to retain ‘in support of the ongoing collaboration with Regeneron’.
Sanofi currently holds approximately 23.2 million shares of Regeneron’s common stock, representing approximately 20.6% ownership.
According to the press release, Sanofi expects to use the net proceeds of the offering and the repurchase to further execute on its strategy to drive innovation and growth.
Paul Hudson, Chief Executive Officer, Sanofi, said that the decision to divest Sanofi’s holdings was ‘fully aligned’ and made in consultation with Regeneron. He added that the collaboration between both companies ‘has been one of the most productive in the industry’, not only in creating significant commercial value, but in the development of ‘important medicines for patients’.
Sanofi and Regeneron first collaborated in 2003, with Sanofi purchasing a shareholding in Regeneron a year later. The long-standing clinical and commercial collaboration has yielded five approved treatments to date with additional candidates currently in clinical development.
Gain access to Sanofi, Regeneron and thousands of equities via IG's world-leading trading and investments platform. With CFDs, you can buy long or sell short on a range of healthcare stocks depending on whether you think prices will rise or fall. Start today by opening a live or demo IG account.
Sanofi maintains 2020 earnings growth forecast at 5%
Sanofi will discontinue accounting for its ownership in Regeneron’s common shares under the equity method, following completion of the proposed public offering and share repurchase.
In lieu of this accounting change, Sanofi expects its earnings per share (EPS) to grow by approximately 5% in 2020 at a constant exchange rate, compared to 2019’s restated business EPS of €5.64. This is in line with Sanofi’s 2020 business EPS growth guidance.
The public offering is occurring simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs, together with Barclays, BNP Paribas, Citigroup, J.P. Morgan, Morgan Stanley as joint book-running managers.
How to trade healthcare stocks with IG
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.